Pharmacogenomics Research - Pharmacology, Designer Drugs, Customized Medicines

Pharmacogenomics Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacogenomics, including details on pharmacology, designer drugs, customized medicines.


Pharmacogenomics Research Today

Home

View Latest Issue

Information About Pharmacogenomics

Books on Pharmacogenomics

Advertising in Research Today

View Other Research Today Publications



Pharmacogenetics of antiarrhythmic therapy.

Darbar D, Roden DM

Vanderbilt Arrhythmia Service, Vanderbilt University School of Medicine, Room 1285A, MRB IV, Nashville, TN 37323-6602, USA. dawood.darbar@vanderbilt.edu

Individuals vary widely in their responses to therapy with most drugs. Indeed, responses to antiarrhythmic drugs are so highly variable that study of the underlying mechanisms has elucidated important lessons for understanding variable responses to drug therapy in general. Variability in drug response may reflect variability in the relationship between a drug dose and the concentrations of the drug and metabolite(s) at relevant target sites; this is termed pharmacokinetic variability. Another mechanism is that individuals vary in their response to identical exposures to a drug (pharmacodynamic variability). In this case, there may be variability in the target molecule(s) with which a drug interacts or, more generally, in the broad biological context in which the drug-target interaction occurs. Variants (polymorphisms and mutations) in the genes that encode proteins that are important for pharmacokinetics or for pharmacodynamics have now been described as important contributors to variable drug actions, including proarrhythmia, and these are described in this review. However, the translation of pharmacogenetics into clinical practice has been slow. To this end, the creation of large, well-characterised DNA databases and appropriate control groups, as well as large prospective trials to evaluate the impact of genetic variation on drug therapy, may hasten the impact of pharmacogenetics and pharmacogenomics in terms of delivering personalised drug therapy and to avoid therapeutic failure and serious side effects.

Published 28 July 2006 in Expert Opin Pharmacother, 7(12): 1583-90.
Full-text of this article is available online (may require subscription).

Place a permanent text-link or advertisement here for just US$15.

© 2005-2008 Pharmacogenomics Research Today. All Rights Reserved.



Pharmacogenomics Research Today Archive:

Volume 1 (2005)
  Issue 1 (October)
  Issue 2 (November)
  Issue 3 (December)

Volume 2 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)



Pharmacogenomics Books

Pharmacogenomics, Second Edition (Drugs and the Pharmaceutical Sciences)

Pharmacogenomics, Second Edition (Drugs and the Pharmaceutical Sciences)